Noxopharm (NOX) Stock Overview
A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
NOX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Noxopharm Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.093 |
| 52 Week High | AU$0.14 |
| 52 Week Low | AU$0.043 |
| Beta | -0.31 |
| 1 Month Change | 1.09% |
| 3 Month Change | -7.00% |
| 1 Year Change | -11.43% |
| 3 Year Change | -41.88% |
| 5 Year Change | -82.29% |
| Change since IPO | -49.73% |
Recent News & Updates
We Think Noxopharm (ASX:NOX) Has A Fair Chunk Of Debt
Dec 04
We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate
Jul 29Recent updates
We Think Noxopharm (ASX:NOX) Has A Fair Chunk Of Debt
Dec 04We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate
Jul 29Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation
Aug 24Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?
Jan 04We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate
Jul 22Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?
Feb 27We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth
Nov 10Is Noxopharm (ASX:NOX) Using Debt Sensibly?
Jun 04Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 17These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively
Sep 04Are Insiders Selling Noxopharm Limited (ASX:NOX) Stock?
Jun 17
Shareholder Returns
| NOX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 10.7% | -1.4% | 0.06% |
| 1Y | -11.4% | -32.5% | 2.4% |
Return vs Industry: NOX exceeded the Australian Biotechs industry which returned -32.5% over the past year.
Return vs Market: NOX underperformed the Australian Market which returned 2.4% over the past year.
Price Volatility
| NOX volatility | |
|---|---|
| NOX Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 18.9% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: NOX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: NOX's weekly volatility (14%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Gisela Mautner | www.noxopharm.com |
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types.
Noxopharm Limited Fundamentals Summary
| NOX fundamental statistics | |
|---|---|
| Market cap | AU$27.18m |
| Earnings (TTM) | -AU$4.88m |
| Revenue (TTM) | AU$2.82m |
Is NOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOX income statement (TTM) | |
|---|---|
| Revenue | AU$2.82m |
| Cost of Revenue | AU$4.27m |
| Gross Profit | -AU$1.45m |
| Other Expenses | AU$3.44m |
| Earnings | -AU$4.88m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | -51.25% |
| Net Profit Margin | -173.15% |
| Debt/Equity Ratio | 359.3% |
How did NOX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/07 07:25 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Noxopharm Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.